News Sentiment

GNTA sentiment intelligence

Genenta Science SpA ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.50 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-12.8% over one week, -19.8% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -12.8% Price reacting lower
Trend fit Trend active -19.8% over four weeks
Fair value -57.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
TradingView 8
Market source 6
The Globe and Mail 5
TradingKey 5
dars.gov.et 2
DonanımHaber 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 16
Deals and strategy 2
Analyst action 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Stock Titan Direct company coverage

Court restores Genenta Science (GNTA) corporate purpose amendment

Genenta Science S.p.A. announced that the Court of Milan has revoked a preliminary order that had suspended the effectiveness of an amendment to its corporate purpose, making the amendment fully effective again. The court granted Genenta's appeal, noting the company's interest in

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 19:46
Source
Stock Titan
Simply Wall Street Direct company coverage

Genenta Science (Nasdaq:GNTA) - Stock Analysis

This report provides a stock analysis for Genenta Science (GNTA), a clinical-stage biotechnology company developing gene therapies for solid tumors. It highlights significant risks including declining earnings, low revenue, share price volatility, and shareholder dilution. Despit

Tone
Negative 39/100
Event
Earnings
Published
10 Jul 2026 05:10
Source
Simply Wall Street
TradingView Direct company coverage

Enterprise value to revenue forward of Genenta Science S.p.A. – NASDAQ:GNTA

This article displays the "Enterprise value to revenue forward" metric for Genenta Science S.p.A. (NASDAQ: GNTA) on the TradingView platform. The content is primarily a data display from TradingView's financial section, indicating the company's valuation. No further financial ana

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 16:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Genenta Science S.p.A. – NASDAQ:GNTA

The article title mentions "Price to book forward of Genenta Science S.p.A. - NASDAQ:GNTA," indicating it is a financial data point for the company Genenta Science S.p.A., which is listed on NASDAQ. The content, however, appears to be an empty or placeholder page from TradingView

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 07:40
Source
TradingView
The Globe and Mail Direct company coverage

Genenta Science Faces Court-Ordered Suspension of Corporate Purpose Amendment While Voting Rights Reform Stands

Genenta Science S.p.A. announced that the Court of Milan upheld a shareholder resolution introducing a multiple voting rights mechanism, supporting long-term shareholding stability. However, the court suspended an October 2025 resolution that broadened Genenta’s corporate purpose

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:10
Source
The Globe and Mail
Stock Titan Direct company coverage

Genenta Science (GNTA) completes Sòphia High Tech deal and resets key vote

Genenta Science (GNTA) has completed its acquisition of a majority equity interest in Sòphia High Tech S.r.l. Shareholders approved the 2025 financial statements and appointed five directors, with co-founder Pierluigi Paracchi re-appointed as Chairman. An Extraordinary Shareholde

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Genenta Science SpA Sponsored ADR – FWB:K5F

This article provides financial data for Genenta Science SpA Sponsored ADR (FWB:K5F), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is presented by TradingView and indicates a market closed status with no recent trades for the stock on the Frank

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 23:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Genenta Science S.p.A. – NASDAQ:GNTA

This article provides financial information for Genenta Science S.p.A. (NASDAQ:GNTA), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from TradingView, displaying key metrics for the pharmaceutical company.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 16:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Genenta Science SpA Sponsored ADR – FWB:K5F

This page displays information regarding the enterprise value to revenue forward for Genenta Science SpA Sponsored ADR (FWB:K5F) on the Frankfurt Stock Exchange. The market was closed, and no trades were recorded. The content is primarily a financial data display from TradingView

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Genenta Science S.p.A. – NASDAQ:GNTA

This article focuses on the "Price to earnings forward" metric for Genenta Science S.p.A. (NASDAQ: GNTA). It appears to be a financial data page from TradingView, providing an overview of the company's financial information. The content itself, however, does not present any speci

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 05:41
Source
TradingView
Stock Titan Direct company coverage

Genenta (GNTA) faces court suspension of broad corporate purpose change

The Court of Milan has issued an interim order regarding Genenta Science S.p.A. (GNTA), denying the suspension of its multiple voting rights mechanism but temporarily suspending a resolution that broadly amended the company's corporate purpose. The court cited concerns that the c

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Genenta Science Sets CEO Severance Terms and Narrows Non-Compete in June 2026

Genenta Science S.p.A. (GNTA) has formalized a severance agreement with CEO Pierluigi Paracchi, providing him with a lump-sum payment equivalent to twelve months of his gross remuneration plus a potential 40% annual bonus upon qualifying termination events. The company also narro

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 12:11
Source
The Globe and Mail
TradingView Direct company coverage

Genenta Science SpA Sponsored ADR Actuals & Estimates (NASDAQ:GNTA)

The article provides an overview of Genenta Science S.p.A. (NASDAQ:GNTA) on TradingView, focusing on its financial actuals and estimates. It highlights access to reported financial data, analyst estimates across various financial statements, and offers tools to compare actual res

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 20:11
Source
TradingView
Stock Titan Direct company coverage

Genenta Science (NASDAQ: GNTA) revises CEO severance package and non-compete

Genenta Science (NASDAQ: GNTA) has updated the severance package and non-compete clause for its CEO, Pierluigi Paracchi, as detailed in a recent 6-K filing. The new "Parachute Agreement" stipulates a lump-sum severance payment equivalent to twelve months of his gross remuneration

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 12:41
Source
Stock Titan
The Globe and Mail Direct company coverage

Genenta Calls June 29 Shareholder Vote on Name Change, Capital Moves and Reverse Split

Genenta Science SpA has scheduled an Ordinary and Extraordinary Shareholders’ Meeting for June 29, 2026, to address significant corporate changes. Shareholders will vote on approving 2025 financial statements, appointing a new Board of Directors, and authorizing share repurchases

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:10
Source
The Globe and Mail
TradingKey Direct company coverage

Genenta Science SPA (GNTA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Genenta Science SPA (GNTA) as presented on TradingKey. It indicates that GNTA has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stoc

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 10:10
Source
TradingKey
TradingKey Direct company coverage

Genenta Science SPA (GNTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Genenta Science SPA (GNTA), but explicitly states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It lists the company's curr

Tone
Negative 40/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey
TradingKey Direct company coverage

Genenta Science SPA (GNTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Genenta Science SPA (GNTA), highlighting its current stock price, market cap, and analyst target price. While it notes the current stock details, it indicates that relevant data for financial forecasting metrics like EPS, Revenue, an

Tone
Positive 60/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Genenta Science SPA (GNTA) Institutional Confidence

This article from TradingKey provides an "Institutional Confidence" overview for Genenta Science SPA (GNTA), listing key shareholders and their respective shareholdings, including recent changes. The stock closed at $1.820 USD, down 2.67%, and has a market cap of $43.41M. Citadel

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 01:10
Source
TradingKey
The Globe and Mail Direct company coverage

Genenta Science Regains Compliance with Nasdaq Minimum Bid Price Rule

Genenta Science (GNTA) announced it has regained compliance with Nasdaq's minimum bid price rule of $1.00 per share, resolving a previous non-compliance issue. This ensures the company's continued listing on the Nasdaq Capital Market, preserving market confidence and access to pu

Tone
Positive 76/100
Event
Market update
Published
17 Jun 2026 13:10
Source
The Globe and Mail
Stock Titan Direct company coverage

Genenta Science (GNTA) sets June meeting on name change and reverse split

Genenta Science (GNTA) has scheduled an all-virtual ordinary and extraordinary shareholders' meeting for June 29, 2026, with a potential second call on June 30, 2026. Shareholders will vote on approving financial statements, appointing a new Board, authorizing treasury share tran

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 13:09
Source
Stock Titan
Investing.com South Africa Direct company coverage

Genenta Science regains compliance with Nasdaq minimum bid price rule By Investing.com

Genenta Science S.p.A. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for ten consecutive business days, resolving a previous non-compliance issue.

Tone
Positive 70/100
Event
Market update
Published
16 Jun 2026 19:40
Source
Investing.com South Africa
Stock Titan Direct company coverage

Genenta Science (NASDAQ: GNTA) regains Nasdaq minimum bid price compliance

Genenta Science (NASDAQ: GNTA) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's American Depositary Shares (ADSs) traded at or above $1.00 per share for 10 consecutive business days from June 1-12, 2026, resolving a previous

Tone
Positive 75/100
Event
Market update
Published
16 Jun 2026 13:39
Source
Stock Titan
Finviz Direct company coverage

GNTA - Genenta Science SpA ADR Options

This page provides an overview of Genenta Science SpA ADR (GNTA) stock options, including financial data, performance metrics, and key statistics. It details the company's market cap, enterprise value, income, sales, and various ratios, alongside insider and institutional ownersh

Tone
Negative 32/100
Event
Market update
Published
12 Jun 2026 04:40
Source
Finviz
Timothy Sykes Direct company coverage

GNTA Stock Sees Volatile Spike As Traders Eye Key Levels

Genenta Science S.p.A. (NASDAQ: GNTA) stock surged over 100% due to progress in its oncology trial, attracting significant trader attention. The company, a micro-cap biotech, has little revenue but holds a solid balance sheet, making it a speculative bet on future potential rathe

Tone
Positive 60/100
Event
Earnings
Published
01 Jun 2026 13:09
Source
Timothy Sykes